Status:
COMPLETED
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborating Sponsors:
University of Pennsylvania
Conditions:
Congenital Hyperinsulinism
Hyperinsulinism
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test...
Detailed Description
For children with congenital hyperinsulinism (CHI), low blood sugar is caused by cells in the pancreas that release too much insulin. Some children with CHI have these cells throughout their pancreas;...
Eligibility Criteria
Inclusion
- Any age, but primarily infants 0-6 months.
- Children with confirmed diagnosis of congenital hyperinsulinism.
Exclusion
- Cases in which surgery will not be considered by parents or guardians.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00674440
Start Date
December 1 2004
End Date
January 1 2009
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104